Aptevo Therapeutics
APVO | NASDAQ
$0.55
-$0.04 (-7.42%)
At close: Nov 16, 2026, 4:00 PM ET
$0.55
$0.00 (-0.47%)
After-hours:
Nov 16, 2026, 5:14 PM ET
Aptevo Therapeutics Company Profile
Company profile explainedCompany Profile
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Key Executives
| Name | Position |
|---|---|
| Jeffrey G. Lamothe | President, Chief Executive Officer & Director |
| Daphne L. Taylor | Senior Vice President & Chief Financial Officer |
| Dirk Huebner | Senior Vice President & Chief Medical Officer |
| Marvin L. White | Executive Chair |
| Mary J. Janatpour | Senior VP & Chief Scientific Officer |
| Miriam Weber Miller | Vice President of Investor Relations & Corporate Communications |
| SoYoung Kwon | Corporate Secretary, Senior Vice President, General Counsel, Business Development & Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 424B5 | Filing |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 23, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 8-K | Current Report |
| Sep 25, 2026 | S-8 | Filing |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 03, 2026 | 424B4 | Filing |
| Sep 03, 2026 | 8-K | Current Report |
| Sep 02, 2026 | EFFECT | Filing |
Aptevo Therapeutics
| Country | United States |
| IPO Date | Jul 20, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Jeffrey G. Lamothe |
Contact Details
2401 4th Avenue Seattle,
Washington 98121 United States
Stock Details
| Ticker Symbol | APVO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671584 |
| CUSIP Number | 03835L702 |
| ISIN Number | US03835L7029 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove APVO